Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Jürgen C. Becker(Düsseldorf University Hospital), Lucie Heinzerling(LMU Klinikum), Jochen Utikal(German Cancer Research Center), Martin Hartmann(Heidelberg University), Rudolf Herbst(Helios Klinikum Erfurt), Alexandra N Spillner(Statistisches Bundesamt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Maria Rita Gaiser, Sebastian Eckhardt(Statistisches Bundesamt), Ioannis Thomas(Sensap (Greece)), Claas Ulrich(Charité - Universitätsmedizin Berlin), Sebastian Haferkamp(University Hospital Regensburg), David Rafei‐Shamsabadi(University Medical Center Freiburg), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Dirk Schadendorf(National Center for Tumor Diseases), Konstantin Drexler(University Hospital Regensburg), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Stephan Grabbe(Goethe University Frankfurt), Elisabeth Livingstone(German Cancer Research Center), Henner Stege(Johannes Gutenberg University Mainz), Thilo Gambichler(Witten/Herdecke University), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Selma Ugurel(Klinikum Bielefeld), Frank Meiß(University of Freiburg), Marlene Garzarolli, Lena M. Wulfken, Lisa Zimmer(The University of Sydney), Leonie Bluhm, Jessica C. Hassel(German Cancer Research Center), Michael Fluck(Fachklinik Hornheide), Winan J. van Houdt(Diakonessenhuis hospital), Tabea Wilhelm(Charité - Universitätsmedizin Berlin), Alexander C. J. van Akkooi(The University of Sydney), Carmen Loquai(Johannes Gutenberg University Mainz), Mirjana Ziemer(University Medical Center), Ulrike Leiter(University of Tübingen), Heidemarie Schinagl, Diamant Thaçi(University of Lübeck), Felix Kiecker(Humboldt-Universität zu Berlin), Heidrun Mitzel-Rink(Johannes Gutenberg University Mainz), Sabine Sell, Martin Kaatz(SRH Wald-Klinikum Gera), Ivonne Kellner, Imke Grimmelmann(Medizinische Hochschule Hannover), Jan C. Simon(University Hospital Leipzig), Kimberley Farmer, Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 75
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k